Preblick Ryan 4
4 · Indivior Pharmaceuticals, Inc. · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Preblick Ryan
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
[F1]2026-03-03$31.98/sh−87,597$2,801,352→ 230,343 total - Exercise/Conversion
Common Stock
[F2][F3]2026-03-03+86,949→ 317,292 total - Exercise/Conversion
Performance Stock Units
[F3][F2]2026-03-03−113,510→ 0 totalExercise: $0.00From: 2028-03-03→ Common Stock (113,510 underlying)
Footnotes (3)
- [F1]In 2024, 204,904 shares vested in respect of performance stock units granted to the Reporting Person on March 3, 2021. These shares were subject to a further two-year holding period. On March 3, 2026, the holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations.
- [F2]Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 86,949 shares vested out of the 113,510 target amount. These shares will be released following a two-year holding period.
- [F3]Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
Signature
/s/Alice Givens, Power of Attorney|2026-03-05